These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12641490)

  • 1. Inhibitors of p38 mitogen-activated protein kinase: potential as anti-inflammatory agents in asthma?
    Newton R; Holden N
    BioDrugs; 2003; 17(2):113-29. PubMed ID: 12641490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits.
    Kaminska B
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):253-62. PubMed ID: 16198162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases.
    Kumar S; Boehm J; Lee JC
    Nat Rev Drug Discov; 2003 Sep; 2(9):717-26. PubMed ID: 12951578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis.
    Pargellis C; Regan J
    Curr Opin Investig Drugs; 2003 May; 4(5):566-71. PubMed ID: 12833650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitogen-activated protein kinases as therapeutic targets for asthma.
    Khorasanizadeh M; Eskian M; Gelfand EW; Rezaei N
    Pharmacol Ther; 2017 Jun; 174():112-126. PubMed ID: 28223227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways.
    Liu W; Liang Q; Balzar S; Wenzel S; Gorska M; Alam R
    J Allergy Clin Immunol; 2008 Apr; 121(4):893-902.e2. PubMed ID: 18395552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tristetraprolin and its role in regulation of airway inflammation.
    Prabhala P; Ammit AJ
    Mol Pharmacol; 2015 Apr; 87(4):629-38. PubMed ID: 25429052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-generation inhibitors demonstrate the involvement of p38 mitogen-activated protein kinase in post-transcriptional modulation of inflammatory mediator production in human and rodent airways.
    Birrell MA; Wong S; McCluskie K; Catley MC; Hardaker EL; Haj-Yahia S; Belvisi MG
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1318-27. PubMed ID: 16368902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting mitogen-activated protein kinases for asthma.
    Duan W; Wong WS
    Curr Drug Targets; 2006 Jun; 7(6):691-8. PubMed ID: 16787171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p38 pathway kinases as anti-inflammatory drug targets.
    Schindler JF; Monahan JB; Smith WG
    J Dent Res; 2007 Sep; 86(9):800-11. PubMed ID: 17720847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle.
    Munoz L; Ramsay EE; Manetsch M; Ge Q; Peifer C; Laufer S; Ammit AJ
    Eur J Pharmacol; 2010 Jun; 635(1-3):212-8. PubMed ID: 20226180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of p38 mitogen-activated protein kinase in ovalbumin and ozone-induced mouse model of asthma.
    Liang L; Li F; Bao A; Zhang M; Chung KF; Zhou X
    Respirology; 2013 Nov; 18 Suppl 3():20-9. PubMed ID: 24188200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia.
    Chialda L; Zhang M; Brune K; Pahl A
    Respir Res; 2005 Apr; 6(1):36. PubMed ID: 15833106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-inflammatory carbazole, LCY-2-CHO, inhibits lipopolysaccharide-induced inflammatory mediator expression through inhibition of the p38 mitogen-activated protein kinase signaling pathway in macrophages.
    Ho FM; Lai CC; Huang LJ; Kuo TC; Chao CM; Lin WW
    Br J Pharmacol; 2004 Mar; 141(6):1037-47. PubMed ID: 14980980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease.
    Saklatvala J
    Curr Opin Pharmacol; 2004 Aug; 4(4):372-7. PubMed ID: 15251131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase.
    Kumar S; Votta BJ; Rieman DJ; Badger AM; Gowen M; Lee JC
    J Cell Physiol; 2001 Jun; 187(3):294-303. PubMed ID: 11319753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (MAPK) inhibitor.
    Lea S; Harbron C; Khan N; Booth G; Armstrong J; Singh D
    Br J Clin Pharmacol; 2015 May; 79(5):756-66. PubMed ID: 25358442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p38 MAP kinase inhibitors: many are made, but few are chosen.
    Dominguez C; Powers DA; Tamayo N
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):421-30. PubMed ID: 16022178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer.
    Yong HY; Koh MS; Moon A
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1893-905. PubMed ID: 19852565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling.
    Das S; Tosaki A; Bagchi D; Maulik N; Das DK
    J Pharmacol Exp Ther; 2006 Jun; 317(3):980-8. PubMed ID: 16525036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.